

## JAKAFI XR - (EQ 11MG BASE; TABLET,EXTENDED RELEASE)

<b>Generic Name</b>	RUXOLITINIB PHOSPHATE	<b>Innovator</b>	None
<b>Dosage</b>	EQ 11MG BASE; TABLET,EXTENDED RELEASE	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of: ? intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. ? polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. ? steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. ? chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## JAKAFI XR - (EQ 22MG BASE, EQ 33MG BASE, EQ 44MG BASE, EQ 55MG BASE; TABLET,EXTENDED RELEASE)

<b>Generic Name</b>	RUXOLITINIB PHOSPHATE	<b>Innovator</b>	None
<b>Dosage</b>	EQ 22MG BASE, EQ 33MG BASE, EQ 44MG BASE, EQ 55MG BASE; TABLET,EXTENDED RELEASE	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	JAKAFI/JAKAFI XR is a kinase inhibitor indicated for treatment of: ? intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults. ? polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea. ? steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. ? chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.